

51304

1475 (55)

**CARCINOGENICITY BIOASSAYS OF VINYL CHLORIDE:
CURRENT RESULTS**

Cesare Maltoni and Giuseppe Lefemine



Reprinted from
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Volume 246, Pages 195-218
January 31, 1975

RSV 0019341

PART II. CARCINOGENESIS ASSOCIATED WITH VINYL CHLORIDE

A. Experimental Studies

CARCINOGENICITY BIOASSAYS OF VINYL CHLORIDE: CURRENT RESULTS

Cesare Maltoni and Giuseppe Lefemine

*Istituto di Oncologia and Centro Tumori
Bologna, Italy*

INTRODUCTION

Vinyl chloride (VC) has been produced in many countries for more than 30 years. It is the constituent of polyvinyl chloride (PVC), which nowadays is the plastic industrial material most used and diffused in the world. Moreover, it is used as a copolymer in Saran and other plastics, as a chemical intermediate, as a solvent, and as a propellant; in the past, for a short period, it was also used as an anesthetic. VC is at present produced at a rate of near 12 million tons per year.

The following population groups may be exposed to VC: (1) workers engaged in the production of PVC and of VC and in the use of VC for other industrial purposes; (2) workers manufacturing PVC; (3) residents in areas neighboring on factories producing PVC and VC; and to a much lesser extent (4) people using products containing VC, as some propellant sprays; (5) people having contact with resins made with VC and with materials containing these resins; and (6) populations consuming food contained in plastics made with VC. Bioassays on the long term effects of VC were not available until 1970.

This situation reflects the limited consideration which has been, up to the present, given to experimental bioassays in predicting the oncogenic effects on man of environmental and occupational agents. In part this is due to industrial and economical interests, in part to deficiencies in technical-scientific facilities, to the dilettantism of many experimental workers, and to the inadequacy of many experiments performed in the past.

What is now happening with vinyl chloride and the story of vinyl chloride carcinogenicity should bring about greater consideration of experimental bioassays and finally induce a new turn in the field of occupational and environmental carcinogenesis. In other words, experimental prediction on the pathogenetic potential of occupational and environmental agents before they are produced and released on a large scale into the human environment should preclude the need for later epidemiological evidence.

HISTORY

In 1970 Professor Viola presented, at the X International Cancer Congress (Houston), the results of a pilot experiment, which then were extensively published in 1971.¹ Professor Viola reported to have observed in 26 rats exposed by inhalatory route to 30,000 ppm of VC 4 h daily, 5 days weekly, for 10-12 months, surviving 10 months or more, 17 skin tumors, 7 pulmonary tumors, mainly carcinomas, and 5 osteochondromas.

In 1967 our Institute started a large investigation, among workers of several Italian industrial plants, to determine the effects of the exposure to different chemicals on respiratory epithelia. The pathological changes were studied by sputum cytology. In 1970 this research was extended also to workers in VC-PVC industries. A significant increase of cellular changes in bronchial epithelium, such as marked squamous metaplasia and squamous dysplasia, were found among the workers more heavily exposed to VC.

Immediately after the Houston Congress, we contacted Professor Viola who kindly put some slides of his experimental tumors at our disposal. According to our interpretation, the malignant tumors observed by Professor Viola in the skin were carcinomas arising from the Zymbal gland (a sebaceous gland of the exterior acoustic duct), which is responsive to a large number of carcinogens. The malignancies of the lung, in our opinion, were metastases from Zymbal gland tumors.

At that time (end of 1970) we planned a project of correlated investigations to further clarify the type and degree of the carcinogenic risk from VC. The project was encouraged and supported by Montedison (Italy), which later was joined by other major European companies, that is, ICI (U.K.), Solvay (Belgium), and Rhone-Progil (France).

The Head of the Health Services of Montedison supplied us with all the technical data dealing with occupational exposure; this made possible the reproduction in our experiments of the most important parameters of occupational conditions.

PLANNING, MATERIALS, AND METHODS

This project included a series of experiments, which were started in sequence. They were designed to study the effects of VC, administered through different routes (inhalation, ingestion, and peritoneal and subcutaneous injection), at different concentrations, for varying periods of time, by continuous or intermittent treatment, on animals of different species (rats, mice, hamsters), strains (Sprague-Dawley and Wistar rats), sex and age (adults, newborns, embryos).

The planning of the program and the preparation of suitable experimental conditions, particularly the building of an apparatus for inhalatory exposure, took us until May 1971. In July 1971 we started experimenting. The chambers of exposure are built basically of stainless steel and glass. They have been designed to deliver concentrations varying from 30,000 to 1 ppm of VC, and to treat simultaneously nearly 1,500 rodents. The VC concentration in the chambers is controlled by gas chromatography.

The VC is supplied by Montedison. Each stock is analyzed in the Montedison Research Unit. The impurities and their maximal levels in the VC employed have been as follows:

H ₂ O	100 ppm
Acetic aldehyde	5 ppm
Acetylene	2 ppm
Allene	5 ppm
Butane	8 ppm
1,3-Butadiene	10 ppm
Chlorophene	10 ppm
Diacetylene	4 ppm
Vinyl acetylene	10 ppm
Propine	3 ppm
Methyl chloride	100 ppm

The experiments utilized mainly Sprague-Dawley rats; Wistar rats, Swiss mice, and hamsters have also been used. All the animals, except the hamsters, are bred in our Institute for years and, whatever their use, are all examined at death by complete autopsy, giving us extensive information concerning their current pathology.

The animals have been weaned and classified by sex when 4-5 weeks old, at which time they have been numbered by ear punch and divided into groups by litter distribution. From weaning, the animals have been fed, *ad libitum*, an adequate commercial diet. During the period of treatment, the animals are housed in groups of 10 in stainless steel wire cages with a solid bottom of the same metal. After the period of experimental treatment, the animals are kept in groups of 5 in makrolon cages, with tops made of stainless steel wire. A shallow layer of white wood shavings serves as bedding. The animals are kept in a temperature-controlled laboratory at 19-20°C.

Fifteen experiments have been started in sequence. Some of them were programmed at the beginning; for some others the need appeared on the basis of the first experimental results. The plan of the experiments and the up-to-date situation is shown in TABLE 1.

Experiment 1 studies the effect of the atmospheric exposure to 10,000, 6,000, 2,500, 500, 250, 50 ppm of VC, 4 h daily, 5 days weekly, for 12 months. Two groups of animals were added as control: one untreated, as for all the following experiments, and one treated with vinyl acetate (VA) at 2,500 ppm, under the same conditions. This dose of VA appeared to be the maximum possible dose for a chronic exposure.

Experiment 2 was performed to investigate in a larger number of animals the effect of doses between 250 to 50, that is 200, 150 and 100, under the same conditions as in Experiment 1. It was started after it was clear that a dose of 250 ppm was still showing oncogenic effects.

Experiment 3 was planned to study the effects of a shorter period of exposure, keeping all the other conditions of Experiment 1.

Experiment 4 studies the effects of the same type of exposure as in Experiment 1 in another species (mice). The treatment lasted 7 months in consideration of the higher mortality and the shorter life span of the mice of our line as compared with rats.

Experiment 5 was undertaken as a pilot investigation on the possible effects of the atmospheric exposure, during pregnancy, on offspring.

Experiment 6 was planned to reproduce the same conditions as in Professor Viola's experiments.

Experiment 7 was planned to study the effects of the same type of exposure as in Experiment 1 in another strain of rats (Wistar).

Experiment 8 studies the effects of the same exposure as in Experiment 1, in a third species (hamsters) for the same period as in Experiment 4.

Experiment 9 was planned, before tumors were observed at 50 ppm in experiment BT1, to assess further whether inhalation of VC has any effect at a dose level of 50 ppm.

Experiment 10 studies whether a high, but limited and/or intermittent atmospheric exposure has any effect.

Experiment 11 was performed to evaluate the effects of VC by ingestion.

Experiment 12 studies the third general route of exposure.

Experiment 13 was started to assess whether VC acts on tissues directly or through metabolites.

Experiment 14 has been included to study the responsiveness of newborns.

TABLE 1
PLAN OF THE EXPERIMENTS UP TO MAY 5, 1974

Exp. No.	Treatment			Animals							Length of the Experiments at the Present Date (weeks)
	Route	Doses of VC	Length	Species	Strain	Age (weeks)	No.				
							♀	♂	Total	Per group	
BT1	Inhalation	10,000, 6,000, 2,500, 500, 250, 50 ppm Untreated controls Treated controls: VA 2,500 ppm	4 h daily, 5 days weekly, 52 wk	Rat	Sprague-Dawley	13	268	309	577	64-96	135 (Ended)
BT2	Inhalation	200, 150, 100 ppm Untreated controls	4 h daily, 5 days weekly, 52 wk	Rat	Sprague-Dawley	13	280	265	545	120-185	43
BT3	Inhalation	10,000, 6,000, 2,500, 500, 250, 50 ppm Untreated controls	4 h daily, 5 days weekly, 17 wk	Rat	Sprague-Dawley	21	262	288	550	60-190	68
BT4	Inhalation	10,000, 6,000, 2,500, 500, 250, 50 ppm Untreated controls	4 h daily, 5 days weekly, weekly, 30 wk	Mouse	Swiss	11	250	260	510	60-150	43
BT5	Transplacental	10,000, 6,000 ppm	4 h daily, 7 days (from 12th to 18th day of pregnancy)	Rat	Sprague-Dawley	19 (breeders) 12 days (embryos)	110	36	146	30-34	77
BT6	Inhalation	30,000 ppm	4 h daily, 5 days weekly, 52 wk	Rat	Sprague-Dawley	17	30	30	60	60	43
BT7	Inhalation	10,000, 6,000, 2,500, 500, 250, 50 ppm Untreated controls	4 h daily, 5 days weekly, 52 wk	Rat	Wistar	11	—	220	220	30-40	43
BT8	Inhalation	10,000, 6,000, 2,500, 500, 250, 50 ppm Untreated controls	4 h daily, 5 days weekly, 30 wk	Hamster	Golden	11	—	268	268	32-70	30
BT9	Inhalation	50 ppm Untreated controls	4 h daily, 5 days weekly, 52 wk	Rat	Sprague-Dawley	11	200	200	400	100 (c) 300 (t)	15

RSV 0019345

BT10	Inhalation	10,000, 6,000 ppm Untreated controls	4 h daily, 5 days weekly, 5 wk; 4 h daily, 1 day weekly, 25 wk; 1 h daily, 4 days weekly, 25 wk	Rat	Sprague- Dawley	11	420	420	840	120	15
BT11	Ingestion	16.6, 33.2, 50 mg/kg body weight in olive oil	5 times weekly, 52 wk	Rat	Sprague- Dawley	13	160	160	320	80	15
BT12	Endoperitoneal Injection	Controls: olive oil 4.25 mg in 1.0 cc olive oil Controls: 1.0 cc olive oil	4, 3, 2, times by 2 months and once	Rat	Sprague- Dawley	13	150	150	300	60	15
BT13	Subcutaneous Injection	4.25 mg in 1.0 cc olive oil Controls: 1.0 cc olive oil	1 Injection	Rat	Sprague- Dawley	21	80	70	150	75	15
BT14	Inhalation	10,000, 6,000 ppm	4 h daily, 5 days weekly, 5 wk	Rat	Sprague- Dawley	1 day	45	44	89	43-46	10
BT15	Inhalation	25, 10, 5 ppm Untreated controls	4 h daily, 5 days weekly, 52 wk	Rat	Sprague- Dawley	13	240	240	480	120	Just started

TABLE 2
EXPERIMENT BT1: RESULTS AFTER 135 WEEKS (END OF THE EXPERIMENT)

Groups and Treatment	Animals (Sprague-Dawley Rats)		Animals with Tumors															Total ^{1/}	
			Zymbal gland carcinomas ^b			Nephroblastomas ^a			Angiosarcomas			Subcu- taneous angio- mas	Skin carci- nomas	Hepa- tomas	Brain neuro- blasto- mas	Other type and/or sites ^a			
	Liver ^d																		
	Total	Cor- rected No.	No.	%	Average latency time (wk)	No.	%	Average latency time (wk)	No.	%	Average latency time (wk)						Other sites		
I: VA, 2,500 ppm	96	49																	
II: VC, 10,000 ppm	69	61	16	26	50	5	8	59	9	15	64	3 ^e	4	3	1	7	7 ^a	38	
III: VC, 6,000 ppm	72	60	7	12	62	4	7	65	13	22	70	3 ^e	3	1	1	3	8 ^e	31	
IV: VC, 2,500 ppm	74	59	2	3	33	6	10	74	13	22	78	3 ^a	3	1	2	5	4 ^e	32	
V: VC, 500 ppm	67	59	4	7	79	4	7	83	7	12	81	2 ^m	1	1	3		4 ^a	22	
VI: VC, 250 ppm	67	59				6	10	80	4	7	79	2 ^e		4			3 ^a	16	
VII: VC, 50 ppm	64	59				1	2	135	1	2	135	1 ^e	1	1			9 ^a	10	
VIII: No treatment	68	58															10 ^a	6	
Total	577	464	29			26			47			14	12	11	7	15	45	155	

RSV 0019347

• Alive animals after 26 weeks, when the first tumor (a Zymbal gland carcinoma) was observed. The percentages are referred to the corrected number.

- Metastases to lung.
- Metastases to liver, lung, spleen, and brain.
- Metastases to lung.
- Several cases of breast fibroadenomas, adrenal and pituitary tumors (generally adenomas) have not been considered, since their distribution in the different groups does not vary.
- Several animals with 2 or more tumors.
- One angiosarcoma of the lips; 1 angiosarcoma of the nose; 1 intraabdominal angiosarcoma (next to liver).
- Two Zymbal gland adenomas; 3 mammary carcinomas; 1 neurilemmoma; 1 ovarian cystadenocarcinoma.
- One angiosarcoma in subcutaneous fibrosing angioma; 1 ossifying paraauricular angiosarcoma; 1 intraabdominal angiosarcoma (next to liver).
- Four Zymbal gland adenomas; 1 salivary gland adenocarcinoma; 2 hepatic and 1 peritoneal angiomas.
- Two intraabdominal angiosarcomas (1 next to spleen and 1 next to ovary); 1 ossifying angiosarcoma of neck.
- One Zymbal gland adenoma; 1 mammary carcinoma; 2 ependymomas.
- One pulmonary angiosarcoma; 1 angiosarcoma of uterus.
- One mammary carcinoma; 2 lymphomas; 1 pulmonary fibrosarcoma.
- One intraabdominal angiosarcoma (next to spleen); 1 intrathoracic ossifying angiosarcoma.
- One Zymbal gland adenoma; 1 mammary carcinoma; 1 lymphoma.
- One intraabdominal diffused angiosarcoma.
- Three Zymbal gland adenomas; 2 mammary carcinomas; 1 subcutaneous angiopericytoma; 3 uterine adenocarcinomas (1 with sarcomatous component).
- One invasive acanthoma of Zymbal gland; 1 subcutaneous fibrosarcoma; 2 peritoneal fibroangiomas; 2 uterine adenocarcinomas (1 with sarcomatous component); 1 uterine leiomyosarcoma; 1 ovarian fibrosarcoma; 1 pulmonary rhabdomyosarcoma; 1 lymphoma.

Experiment 15 was started as soon as we found 1 liver angiosarcoma, 1 extrahepatic angiosarcoma, and 1 nephroblastoma in 3 animals of the first experiment, exposed to 50 ppm of VC for 1 year, and surviving 135 weeks from the beginning of the treatment.

The animals are controlled weekly and weighed every 2 weeks during the period of treatment and monthly after the treatment is over. All the detectable gross pathological changes are recorded during the control. All the animals are kept under observation until spontaneous death. The animals, when moribund, are isolated, in order to avoid cannibalism.

A complete autopsy is made on each animal. Histological examinations are performed on Zymbal glands, interscapular brown fat, salivary glands, tongue, lungs, liver, kidneys, spleen, stomach, different segments of the intestine, bladder, brain, bones of the legs and feet, and any other organ with pathological lesions.

All the animals exposed to the highest doses (30,000 and 10,000 ppm), with or without tumors, are examined radiologically, during treatment and/or at death; moreover, radiological examinations are made on all animals bearing tumors, although exposed to the lower doses.

RESULTS

The current results of several experiments are shown in the TABLES 2-9. Some others are still not available.

Tumors of different types may be present in the same animals.

Zymbal gland carcinomas may be bilateral. Histologically they may reproduce, to some extent, the structure of the normal Zymbal gland (FIGURE 1), but often they present squamous, glandular, solid, anaplastic, and polymorphous patterns. Several of these different pictures may be observed in the same tumor. Metastases of these tumors are sometimes found in the lung (FIGURE 2).

Nephroblastomas are often bilateral. Their histological picture reminds us of an embryonal kidney (FIGURE 3). They metastasize to the liver, spleen, lung, and brain. Hyperplasia of nephroblastoma-like tissue is often observed in the kidney of treated rats, with or without nephroblastoma.

Angiosarcomas and angiomas may be found at more than one site in the same animal. In liver they are often polycentric. Hepatic and extrahepatic angiosarcomas are more or less differentiated (FIGURES 4-9). They are morphologically

TABLE 3
EXPERIMENT BT6: RESULTS AFTER 41 WEEKS

Groups and Treatment	Animals (Sprague-Dawley Rats)			Animals with Tumors							
	Total	Corrected No. ^a (a)	Survivors	Zymbal gland carcinomas			Nephroblastomas	Angiosarcomas		Other type and/or site	Total
				No.	%	Average latency time (wk)		Liver	Other sites		
I: VC, 30,000 ppm	60	60	48	12	20	35					12

* Animals alive after 24 weeks, when the first tumor (a Zymbal gland carcinoma) was observed. The percentages are referred to the corrected number.

RSV 0019349

TABLE 4
EXPERIMENT BT2: RESULTS AFTER 41 WEEKS

Groups and Treatment	Animals (Sprague-Dawley Rats)		Animals with Tumors			
	Total	Survivors	Zymbal gland carcinomas	Nephroblastomas	Angiosarcomas	Other type and/or site
I: VC, 200 ppm	120	115				1*
II: VC, 150 ppm	120	109				
III: VC, 100 ppm	120	112				
IV: No treatment	185	171				
Total	545	507				1

* One subcutaneous fibroangioma.

similar in rats, mice, and hamsters. Angiosarcomas frequently metastasize; as far as the liver angiosarcomas are concerned, the lung is the most frequent site of distant metastases.

Blood vessels ectasias, endothelial hyperplasia, associated or not associated with cellular atypia, are often observed in the liver and in other organs and tissues in treated animals, with or without local or distant angiosarcomas or angiomas. Therefore, the effect of VC on blood vessels and endothelia should be considered systematic.

Angioblastic proliferation, angiomas, and angiosarcomas in the liver and in other sites may or may not be associated with fibroplasia. From the histological observations, the sequence of local changes in the genesis of malignant vascular tumors appears to be as follows: endothelial hyperplasia, angiomas, atypias of endothelial cells in hyperplasia (dysplasia) and angiomas, angiosarcomas.

Fibroangioblastic proliferation undergoing fibrosis is frequently observed in the spleen of the treated rats and mice.

Skin carcinomas in treated rats appear frequently to arise from sebaceous glands, of which they may reproduce in some extent the morphological characters (FIGURE 10).

The hepatomas observed in treated rats are usually well differentiated. Metastases have been observed in the lung.

Brain neuroblastomas are very similar to the human medulloblastomas (FIGURE 11). Since they may be quite small and therefore not easily macroscopically detectable, we are now making serial sections of the brains of the treated rats, to obtain more precise information on their real incidence.

The lung adenomas in treated mice are usually multicentric; their number is higher in animals treated with heavier doses. Many of these tumors appear to undergo early malignant transformation.

Mammary carcinomas may be solitary or multiple. They are usually well differentiated adenocarcinomas, with monomorphous or polymorphous arrangement. The most distinct feature of these tumors is the frequency with which they present areas of squamous metaplasia (FIGURE 12).

Up to the present no acroosteolytic lesion has been observed on our treated animals.

Several of the tumors produced by VC are quite rare or exceptional. To our knowledge liver angiosarcomas, nephroblastomas, and neuroblastomas have

TABLE 3
EXPERIMENT BT3: RESULTS AFTER 66 WEEKS*

Groups and Treatment	Animals (Sprague-Dawley Rats)	Animals with Tumors					
		Total	Sarcinoma	Zymal gland carcinomas	Nephroblas- tomas	Angiosarcomas	
						Liver	Other sites
I: VC, 10,000 ppm	60	29	4 (15)	—	(4)	—	(6)
II: VC, 6,000 ppm	60	42	2 (3)	—	(2)	—	(6)
III: VC, 2,500 ppm	60	51	1 (2)	—	(4)	—	(5)
IV: VC, 500 ppm	60	54	—	(1)	—	—	(1)
V: VC, 250 ppm	60	39	—	—	1	—	(2)
VI: VC, 50 ppm	60	41	—	—	—	—	—
VII: No treatment	190	166	—	—	—	—	—
Total	550	422	7 (21)	1 (10)	—	(20)	(5)
						3 (10)	5 (21)
							16 (73)

* In parentheses are recorded the tumors found in experiment BT1 after 66 weeks.

† One fibroepithelial papilloma of the skin.

‡ One squamous carcinoma of the skin; 1 subcutaneous angiosarcoma.

§ One lymphoma.

¶ One lymphoma.

TABLE 6
EXPERIMENT BT7: RESULTS AFTER 41 WEEKS

Groups and Treatment	Animals (Wistar Rats)		Animals with Tumors*					
	Total	Survivors	Zymbal gland carci- nomas	Nephro- blas- tomas	Angiosarcomas		Other type and/or site	Total
					Liver	Other sites		
I: VC, 10,000 ppm	30	27	— (1)				— (1)	— (2)
II: VC, 6,000 ppm	30	26				— (1)		— (1)
III: VC, 2,500 ppm	30	23	— (1)					— (1)
IV: VC, 500 ppm	30	27	— (1)					— (1)
V: VC, 250 ppm	30	26					1†	1
VI: VC, 50 ppm	30	28						
VII: No treatment	40	38						
Total	220	195	— (3)			— (1)	1 (1)	1 (5)

* In parentheses are recorded the tumors found in male Sprague-Dawley rats of experiment BT1, after 41 weeks.

† One angioma of the cecum.

TABLE 7
EXPERIMENT BT5: RESULTS AFTER 75 WEEKS

Groups and Treatment	Animals (Sprague-Dawley Rats)		Animals with Tumors					
	Total	Survivors	Zymbal gland carci- nomas	Nephro- blas- tomas	Angiosarcomas		Other type and/or site	Total
					Liver	Other sites		
I: VC, 10,000 ppm (breeders)	30	21						
II: VC, 6,000 ppm (breeders)	30	24						
III: VC, 10,000 ppm (offsprings)	54	48				1*		1
IV: VC, 6,000 ppm (offsprings)	32	30				1†		1
Total	146	123				2		2

* Subcutaneous angiosarcoma on a 24-week-old male.

† Subcutaneous angiosarcoma on a 22-week-old female.

never been described as spontaneously occurring in rats. Liver and extrahepatic angiosarcomas have been induced only in a few instances in experimental rodents (rats, hamsters, and mice) (for references see Maltoni and Lefemine⁹). As far as we know this is the first time that nephroblastomas and neuroblastomas have been experimentally reproduced.

CONCLUSIONS

1. Under our experimental conditions, VC produced tumors in the three animal species studied: rats, mice, and hamsters (as far as the last species is concerned, the data should still be considered as preliminary).

RSV 0019352

TABLE 8
EXPERIMENT BT4: RESULTS AFTER 41 WEEKS

Groups and Treatment	Animals (Rues Mice)						Animals with Tumors					
	Total		Corrected number*		Survivors		Pulmonary tumors*		Mammary carcinomas*		Liver angiosarcomas	
	♂	♀	♂	♀	♂	♀	No.	%	No.	%	Average latency time (wk.)	Average latency time (wk.)
I: VC, 10,000 ppm	30	30	60	22	28	30	1	7	8	27	34	28
II: VC, 6,000 ppm	30	30	60	26	28	54	4	12	16	22	40	33
III: VC, 2,500 ppm	30	30	60	23	30	53	9	15	24	12	22	35
IV: VC, 500 ppm	30	30	60	29	29	58	7	21	28	16	27	34
V: VC, 250 ppm	30	30	60	29	29	58	19	14	33	11	34	30
VI: VC, 50 ppm	30	30	60	27	30	57	11	18	29	7	35	35
VII: No treatment	80	70	150	74	67	141	51	57	108	1	0.7	39
Total	260	250	510	240	241	471	102	144	246	89	36	

* Alive animals after 16 weeks, when the first tumor (a mammary carcinoma) was observed. The percentages are referred to the corrected number.

* Adenomas, some of which undergoing malignant transformation.

* In females.

* Several animals with 2 or more tumors.

* Three subcutaneous angiosarcomas; 2 liver fibrosarcomas; 1 heart fibrosarcoma; 1 ossifying interscapular angiosarcoma.

* One squamous carcinoma and 1 invasive acanthoma of the skin.

* One hepatic angiosarcoma.

* One squamous carcinoma and 1 acanthoma of the skin; 1 squamous carcinoma of the nose.

* One lymphoma.

* One renal angiosarcoma.

* One squamous carcinoma and 1 acanthoma of the skin.

* One subcutaneous angiosarcoma.

* One acanthoma of the skin.

* One hepatic angiosarcoma.

* Two subcutaneous angiosarcomas; 2 hepatic fibrosarcomas.

TABLE 9
EXPERIMENT BT8: RESULTS AFTER 28 WEEKS

Groups and Treatment	Animals (Golden Hamsters)		Animals with Tumors				
	Total	Survivors	Liver angio- sarcomas	Skin tricho- epithel- omas	Lymph- omas	Melan- omas	Total*
I: VC, 10,000 ppm	35	19		1			1
II: VC, 6,000 ppm	32	21		1	1	1	3
III: VC, 2,500 ppm	33	19					
IV: VC, 500 ppm	33	23	—†		1		1
V: VC, 250 ppm	32	18					
VI: VC, 50 ppm	33	23			1		1
VII: No treatment	70	49					
Total	268	172		2	3	1	4

* One animal with 3 tumors.

† At the date (September 1974) on which the final draft of this report was submitted for publication, 1 liver angiosarcoma with pulmonary metastases was observed in this group.




FIGURE 1. Well differentiated Zymbal gland carcinoma in rat. H&E, $\times 190$.




FIGURE 2. Pulmonary metastasis of well differentiated Zymbal gland carcinoma in rat. H&E, $\times 190$.

2. The range of induced tumors varies to some extent from species to species. When given by inhalation VC produced: in rats, Zymbal gland carcinomas, nephroblastomas, angiosarcomas, and angiomas of the liver and other sites, skin carcinomas, hepatomas, and brain neuroblastomas; in mice, lung adenomas (frequently undergoing malignant transformation), mammary carcinomas, of a peculiar type, angiosarcomas and angiomas of the liver and of other sites, skin epithelial tumors; in hamsters, liver angiosarcomas and, as early evidence seems to suggest, skin trichoepitheliomas and lymphomas. Incidentally, liver angiosarcomas have been observed in all three animal species.

3. In the BT1 and BT4 experiments, VC shows a carcinogenic effect at 50 ppm.

4. From the BT1 experiment (the only one completed) a dose-response rela-



FIGURE 3. Nephroblastoma in rat. H&E, $\times 470$.

relationship clearly emerges, as far as angiosarcomas and nephroblastomas are concerned, in the lower dose ranges: from 500 to 50 ppm for angiosarcomas and from 250 to 50 ppm for nephroblastomas.

5. A comparison of the results available at the present moment in rats exposed for 12 and 4 months (BT1 and BT3 experiments) shows that the neoplastic response, as far as angiosarcomas and nephroblastomas are concerned, is affected by the length of exposure to VC.

6. The comparison of the results obtained in rats of two different strains, i.e., Sprague-Dawley (BT1) and Wistar (BT7), at the present moment, seems to suggest that the strain factor considerably affects the neoplastic response.

7. The onset of two subcutaneous angiosarcomas in the offspring of breeders exposed during pregnancy for 7 days appears to indicate a transplacental effect of VC.



FIGURE 4. Liver angiosarcoma in rat. H&E, $\times 190$.

8. The observation of a few cases of ossifying angiosarcomas suggests a new orientation in the pathogenetic interpretation of acroosteolysis in workers exposed to VC.

The results presented in this report should be considered both preliminary and incomplete: preliminary since most of the experiments are still in progress, and some at the initial stages; incomplete because a more profound and systematic microscopical examination, which is now under way, of further serial histological sections, may disclose new initial, minute, undetected tumors. For the latter reason previous reports have been even more incomplete. The release of the preliminary and incomplete results has been made necessary because of the importance



FIGURE 5. Liver angiosarcoma in rat. H&E, $\times 190$.

of the topic, the pressure of the events and the requests. Since there have been more than 100,000 slides up to now, I am sure that those engaged in pathological screening of experimental material are aware of our difficult task.

Our data have been periodically transmitted to the European Companies which have supported our research and are available to all interested parties.

Before the end of 1972, a short time after it was known that VC was inducing in rats not only Zymbal gland tumors, but also nephroblastomas and liver angiosarcomas, these results were also made known to the MCA (U.S.A.). This information promoted clinical observations and epidemiological investigations, which in December 1973 led to the first discovery of a liver angiosarcoma, as an occupational disease, in a worker of a U.S.A. factory producing VC-PVC.




FIGURE 6. Pulmonary metastasis of liver angiosarcoma in rat. H&E, $\times 190$.

RSV 0019359




FIGURE 7. Liver angiosarcoma in mouse associated with fibrosis. H&E, $\times 190$.

RSV 0019360




FIGURE 8. Liver angiosarcoma in mouse associated with fibrosis. H&E, $\times 190$.

RSV 0019361



FIGURE 9. Kidney angiosarcoma in mouse. H&E, $\times 190$.

RSV 0019362




FIGURE 10. Skin sebaceous, well differentiated, carcinoma in rat. H&E, $\times 190$.



FIGURE 11. Brain neuroblastoma with typical rosettes in rat. H&E, $\times 470$.

RSV 0019364



FIGURE 12. Mammary adenocarcinoma with squamous metaplasia in mouse. H&E, $\times 190$.

May I recommend again that the VC carcinogenesis may serve as a convincing example for urgently promoting experimental bioassays for all new industrial compounds and for those compounds that are already widespread but whose effect we still ignore, to avoid occupational cancers.

Our Institute is now undertaking projects of carcinogenicity bioassays of other monomers employed in the plastic industry.

REFERENCES

1. VIOLA, P. L., A. BIGOTTI & A. CAPUTO. 1971. Oncogenic response of rat skin, lungs and bones to vinyl chloride. *Cancer Res.* 31: 516-519.
2. MALTONI, C. & G. LEFEMINE. 1974. Carcinogenicity to bioassays of vinyl chloride. I. Research plan and early results. *Environ. Res.* 7: 387-405.

23273

RSV 0019365